Melanotan 1 vs Melanotan 2: an approved drug versus a gray-market injectable

Almost every “Melanotan 1 vs Melanotan 2” page treats the two as flavors of the same tanning peptide — a milder version and a stronger one. That framing is the single biggest mistake in the entire topic. The two compounds started from the same idea (synthetic analogs of α-melanocyte-stimulating hormone, the hormone that tells your skin to make pigment) and then went in opposite directions. One was developed properly, ran clinical trials, and became an FDA-approved prescription drug for a specific rare disease. The other never did, and circulates as an unapproved injectable sold online for a cosmetic tan. They are not two doses of one thing. They are a drug and a gray-market product that happen to share a family name.

The naming trap: “1” and “2” aren’t dose levels

The numbers are an accident of chemistry history, not a potency scale. Both molecules descend from α-MSH, the natural ligand at the melanocortin-1 receptor (MC1R) that drives skin pigmentation. Researchers built analogs to make that signal more stable and longer-lasting. The compound that became known as Melanotan I is a comparatively focused melanocortin agonist; the one called Melanotan II was engineered as a more potent, broader agonist that also hits other melanocortin receptors. So “2” isn’t a higher dose of “1” — it’s a different molecule with a wider receptor footprint, and that footprint is exactly what splits their stories.

Melanotan I: the one that became a real, approved drug

Melanotan I was developed into afamelanotide, marketed as Scenesse, and it is a legitimate prescription medicine. Crucially, it is not approved as a tanning agent. Its approval is for erythropoietic protoporphyria (EPP) — a rare inherited disorder in which sunlight causes severe, burning skin pain. Afamelanotide is delivered as a controlled subcutaneous implant placed by a clinician, not a vial someone injects at home, and it raises eumelanin to give light-tolerance, reducing phototoxic pain.

That clearance is backed by genuine randomized data. In the pivotal trials published in the New England Journal of Medicine, afamelanotide implants increased the pain-free time EPP patients could spend in light and improved their quality of life versus placebo.^[1] This is the part the “MT-1 for tanning” copy erases: afamelanotide is a clinically supervised therapy for a painful disease, dispensed and implanted under medical control. The cosmetic tan is a side property of the mechanism, not the reason the drug exists or is approved.

Melanotan II: the unapproved cosmetic injectable

Melanotan II (MT-2) is the one almost everyone actually means when they search for “melanotan.” It is not approved in any country. It is sold gray-market as a powder to reconstitute and inject for two off-label purposes: a faster, deeper tan and an unexpected side effect that became a selling point — spontaneous erections, traced to its activity at the MC4R receptor. That broader receptor reach is also why MT-2 so reliably produces nausea, facial flushing and appetite suppression. We cover the molecule’s evidence and dosing reality in depth in our Melanotan II evidence review; here the point is the contrast: nothing about MT-2 went through the approval process afamelanotide did.

Because it’s unregulated, MT-2 also carries documented harms. A dermatology review of unregulated α-MSH analogues catalogued the pattern — new and darkening moles, systemic effects, and the absence of any quality control over what’s in the vial.^[2] Case reports back this up: dermoscopy studies have documented changes in melanocytic nevi during MT-2 use,^[3]and urology literature records priapism — a prolonged, painful erection that is a medical emergency — from melanotan tanning injections.^[2][4] The MC4R-driven sexual mechanism is the same one exploited deliberately by the approved drug bremelanotide (PT-141), which is worth contrasting: PT-141 went through trials and approval for sexual dysfunction; MT-2’s erections are an uncontrolled side effect of a product no regulator has cleared.

Receptor selectivity: the pharmacology that explains everything

If you understand one thing about MT-1 versus MT-2, make it this: which receptors each one hits. Pigmentation runs through MC1R. Afamelanotide (Melanotan I) is the more MC1R-weighted agonist — it drives the pigment pathway that gives EPP patients light-tolerance, which is precisely why it could be developed for that single, focused indication. Melanotan II is a broadermelanocortin agonist whose reach extends into MC4R, the receptor tied to sexual function and appetite. That extra MC4R activity is the entire reason MT-2 produces erections and nausea that afamelanotide largely does not. So MT-2 isn’t “stronger Melanotan 1” — it’s a less selective molecule, and its lower selectivity is the source of both its notoriety and its side-effect burden.

The honest verdict

Match the name to reality, not to the marketing. Melanotan I is afamelanotide — a real, FDA-approved melanocortin drug, given as a supervised implant, for the narrow purpose of relieving light-pain in erythropoietic protoporphyria. It is not a tanning product you can legitimately buy, and its tan is a side property of a disease therapy. Melanotan II is the gray-market injectable— unapproved anywhere, sold for cosmetic tanning and libido, broader at the receptor level, and attached to documented harms with zero quality control. If you came here trying to pick the “better tanning peptide,” the honest answer is that the comparison itself is a category error: one item is a controlled clinical drug for a rare disease, and the other is an unregulated cosmetic gamble. For the full picture on the product most people are actually weighing, read our Melanotan II evidence review, sit it against the wider catalog in the peptide evidence matrix, and — if your interest is in legitimate, vetted peptide options — start with how this market is priced in peptide therapy cost and which providers we rate in our best peptide therapy comparison.